Abstract
Diabetes is a serious and escalating global health problem. The global prevalence is 8.3 % and 387 million people are currently affected [1]. Over 45 % of people with type 2 diabetes are undiagnosed and the total number affected is predicted to rise to 592 million by 2035. An additional 316 million people are estimated to have impaired glucose tolerance and many of these will progress to type 2 diabetes. For example, in the UK, the prevalence of diabetes is 6.0 %, affecting 3.2 million people, while in the USA, the prevalence is 12 % of the population.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
International Diabetes Federation (IDF). IDF diabetes atlas, 6th Edition; 2014. www.idf.org. Accessed 5 Sept 2016.
Scottish Diabetes Survey Monitoring Group. Scottish diabetes survey 2013. National Health Service (NHS) Scotland. www.diabetesinscotland.org.uk. Accessed 5 Sept 2016.
World Health Organization (WHO). Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. WHO; 2006. www.who.int/diabetes/publications/diagnosis_diabetes2006/en/. Accessed 5 Sept 2016.
American Diabetes Association (ADA). Standard of medical care in diabetes - 2016. Diabetes Care. 2016;39 Suppl 1:S1–2.
Bailey C. Antidiabetic drugs. Br J Cardiol. 2000;7:350–60.
Defronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–94.
Defronzo RA. From the triumvirate to the Omnious Octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95.
Petersen KF, Dunfour S, Morino K, Yoo PS, Cline GW, Shulman GI. Reversal of muscle insulin resistance by weight reduction in young, lean, insulin-resistant offspring of parents with type 2 diabetes. Proc Natl Acad Sci U S A. 2012;109:8236–40.
Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present and future. Lancet. 2014;383:1068–83.
Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab. 2004;89:3629–43.
Perl S, Kushner JA, Buchholz BA, Meeker AK, Stein GM, Hsieh M, et al. Significant human β-cell turnover if limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. J Clin Endocrinol Metab. 2010;95:E234–9.
Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24:382–91.
Klein BE, Klein R, Moss SE, Cruickshanks KJ. Parental history of diabetes in a population-based study. Diabetes Care. 1996;19:827–30.
Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins. A study of 200 pairs. Diabetologia. 1981;20:87–93.
Schulz LO, Bennett PH, Ravussin E, Kidd JR, Esparza J, Valencia ME. Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care. 2006;29:1866–71.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Cowan, J. (2017). Overview of Type 2 Diabetes. In: Essentials of SGLT2 Inhibitors in Diabetes. Adis, Cham. https://doi.org/10.1007/978-3-319-43296-0_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-43296-0_1
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-43294-6
Online ISBN: 978-3-319-43296-0
eBook Packages: MedicineMedicine (R0)